Opinion|Videos|March 4, 2025
A Review of Current and Emerging Clinical Data for 3L mRCC
Author(s)Pedro Barata, MD, MSc, FACP
An expert discusses how efficacy and safety data from trials such as METEOR, TIVO-3, TiNivo-2, and LITESPARK-005 guide third line (3L) renal cell carcinoma (RCC) treatment. Differences in trial populations, evolving long-term trends, and prior immune checkpoint inhibitor (ICI) use impact applicability. CONTACT-03 and TiNivo-2 provide key insights, and real-world data and patient-reported outcomes refine clinical decision-making. Community oncologists should critically assess study limitations and evolving evidence when selecting therapy.
Episodes in this series
Video content above is prompted by the following:
- Please provide a brief overview of the efficacy and safety data supporting these options, as appropriate (eg, phase 2 Study 205, METEOR, control arm of CONTACT-03, TIVO-3, control arm of TiNivo-2, LITESPARK-005).
- How do the populations of these trials compare?
- What are the trends that have emerged with long-term follow-up?
- What guidance can you offer community oncologists when critically weighing the evidence from studies of these 3L options?
- What are the limitations of applying data from older studies in modern practice (eg, prior ICI)?
- What was learned from the CONTACT-03 and TiNivo-2 studies?
- Are there any patient-reported outcomes from these studies or real-world data that you consider informative to practice?
Related Content
Advertisement
